1. Volume 121, Issue 2, Pages 268-274 (August 2001)
A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active crohn's disease 
Fiona H. Gordon, Clement W.Y. Lai, Mark I. Hamilton, Miles C. Allison, Emmanuel D. Srivastava, Marilyn G. Fouweather, Stephen Donoghue, Carol Greenlees, Javaid Subhani, Peter L. Amlot, Roy E. Pounder 
Gastroenterology 
Volume 121, Issue 2, Pages (August 2001)
DOI: /gast
Copyright © 2001 American Gastroenterological Association Terms and Conditions

2. Fig.1
Trial profile of patients with mild to moderately active Crohn's disease who received 3 mg/kg natalizumab or placebo by double-blind randomization.
Gastroenterology  , DOI: ( /gast )
Copyright © 2001 American Gastroenterological Association Terms and Conditions

3. Fig.2
Mean CDAI by patient group (LOCF data), weeks 0–4.Bars indicate SD, and numbers above and below indicate number of patients in each group who had begun receiving rescue therapy.
Gastroenterology  , DOI: ( /gast )
Copyright © 2001 American Gastroenterological Association Terms and Conditions

4. Fig.3
Clinical status of patients 2 weeks after a single infusion of 3 mg/kg natalizumab or placebo at 2 weeks postinfusion.Observed differences between groups are not significant.
Gastroenterology  , DOI: ( /gast )
Copyright © 2001 American Gastroenterological Association Terms and Conditions

5. Fig.4
Mean serum natalizumab concentrations of 18 patients after a single 3-mg/kg infusion.Bars indicate SD.
Gastroenterology  , DOI: ( /gast )
Copyright © 2001 American Gastroenterological Association Terms and Conditions

6. Fig.5
Mean lymphocyte counts of patients with Crohn's disease after a single infusion of 3 mg/kg natalizumab (n = 18) or placebo (n = 12).Bars indicate SD.
Gastroenterology  , DOI: ( /gast )
Copyright © 2001 American Gastroenterological Association Terms and Conditions